Hims & Hers Health, Inc. (HIMS)
| Market Cap | 9.34B |
| Revenue (ttm) | 2.21B |
| Net Income (ttm) | 133.79M |
| Shares Out | 227.65M |
| EPS (ttm) | 0.54 |
| PE Ratio | 76.43 |
| Forward PE | 64.17 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 28,931,953 |
| Open | 40.74 |
| Previous Close | 41.52 |
| Day's Range | 39.34 - 41.27 |
| 52-Week Range | 19.15 - 72.98 |
| Beta | 2.40 |
| Analysts | Hold |
| Price Target | 42.80 (+4.31%) |
| Earnings Date | Nov 3, 2025 |
About HIMS
Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supp... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for HIMS stock is "Hold." The 12-month stock price target is $42.8, which is an increase of 4.31% from the latest price.
News
Hims & Hers: GLP-1 Partnership Could Unlock Value
Hims & Hers Health reported strong 3Q25 revenue growth of 49% YoY, despite a GAAP EPS miss and shares falling post-earnings. HIMS is expanding its offerings, including testosterone and potential at-ho...
HIMS CEO Says 'A Little Bit of Craziness' Is The Secret To Building A Global Health Platform
Hims & Hers Health Inc (NYSE:HIMS) isn't just chasing wellness trends — it's building a global health platform. At the company's third-quarter earnings call, CEO Andrew Dudum said the company's next p...
Hims & Hers Health, Inc. (HIMS) Q3 2025 Earnings Call Transcript
Hims & Hers Health, Inc. ( HIMS) Q3 2025 Earnings Call November 3, 2025 5:00 PM EST Company Participants Bill Newby Andrew Dudum - Co-Founder, Chairman & CEO Yemi Okupe - Chief Financial Officer Conf...
Hims & Hers Health Third-Quarter Revenue Jumps as Subscribers Grow
The telehealth platform said revenue rose 49% to $599 million in the latest quarter.
Hims & Hers Stock Pops After Q3 Earnings: Here's Why
Hims & Hers Health, Inc. (NYSE:HIMS) shares popped after the company released its third-quarter earnings report after Monday's closing bell. Hims said it is in active discussions to make Novo Nordisk ...
Hims and Hers misses quarterly profit estimates
Hims and Hers Health missed Wall Street estimates for third-quarter profit on Monday, hit by increased product costs and reduced unit sales in the telehealth company's weight-loss business.
Hims & Hers Health, Inc. Reports Third Quarter 2025 Financial Results
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today announced financial results for the third quarter...
Struggling Healthcare Stock Ripe For Bull Notes
Shares of Hims & Hers Health (HIMS) are headed for their fourth-straight daily drop, down 2.4% to trade at $45.53 at last check, as investors look ahead to the company's third quarter results, due out...
Hims & Hers: Use This Drop Before It's Too Late
Hims & Hers has experienced a hefty sell-off in recent weeks. This sell-off was mainly caused by short-term turbulence, and I expect the company to resolve these issues in the next quarter. HIMS needs...
Hims & Hers: There's Opportunity In This Crash (Upgrade)
Hims & Hers offers a compelling "Buy" opportunity after a 30% pullback, despite recent growth concerns and insider selling. HIMS maintains strong long-term growth targets, aiming for $6.5 billion in r...
Looking For The Next Beyond Meat? Here Are The Top 10 Most Shorted Stocks
Investors searching for the next Beyond Meat, Inc. (NYSE:BYND) — the latest poster child for explosive short squeezes — are eyeing the most shorted stocks as potential candidates for outsized rallies.
Hims & Hers Q3 Preview: Key Metrics I Want To See For Beating 2030 Guidance
I expect Hims & Hers Health, Inc. to show stabilizing ARPU around $54+ per user in Q3 despite the GLP-1 slowdown, which could signal meaningful upside to the company's conservative 2030 guidance. I'm ...
Hims & Hers: Q3 Could Provide Volatility, But The Long-Term Vision Remains Bright
Hims & Hers (HIMS) is emerging as a disruptive force in the obesity treatment market, challenging established GLP-1 drug makers. HIMS has aggressively captured market share, often operating in a legal...
Hims & Hers Health: Roller Coaster Gift
Hims & Hers Health launched menopause and low testosterone products in the last month, expanding its addressable market and supporting its $6.5 billion 2030 revenue target. Recent product launches, in...
Why Hims & Hers stock is failing to retain menopause gains and what comes next?
Hims & Hers Health Inc (NYSE: HIMS) started this week on a positive note after announcing its expansion into menopause-related treatments – a large and underserved market. However, the rally is fading...
Hims & Hers Stock's 150% Surge Is All Fundamentals—No Novo, No Problem
Hims & Hers Health Inc. (NYSE:HIMS) has become one of 2025's most surprising winners, up more than 150% year-to-date and over 200% in the past twelve months. But what's making Wall Street sit up this ...
Hims & Hers: Ramping Up A New Billion-Dollar Segment (Rating Upgrade)
I am upgrading Hims & Hers Health, Inc. to a Buy with an $80 price target, implying 30% upside. The new 'Hers' specialty in Menopause is expected to help the company drive over $1B in Hers segment rev...
How HIMS Stock Rises To $120?
Hims & Hers stock (NYSE: HIMS) increased by 16% yesterday following its announcement about expanding into the treatment of menopause and perimenopause—a strategic shift indicating that the company is ...
Weight-loss drugs shook up the stock market. Menopause treatments could be next.
Hims & Hers is taking aim at menopause and perimenopause in an attempt to tap in to a huge and potentially highly lucrative market.
Hers Launches Menopause and Perimenopause Specialty, Taking the Next Step Toward $1B of Hers Revenue in 2026
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the launch of a new specialty in women's health, offering access to aff...
Hims & Hers to Offer Treatments for Menopause, Perimenopause
Hims & Hers Health said it is now providing menopause care, marking the company's latest push into hormone-replacement therapies.
Hims & Hers to Announce Third Quarter 2025 Financial Results on November 3, 2025
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that it will report third quarter 2025 financial results...
Hims & Hers: Why I'm Betting On HIMS Heading To $100
I see a clear path for Hims & Hers Health to reach $100 a share, and I plan to be there when it gets there. HIMS expects revenue growth to rebound, driven by weight loss and new health offerings, aimi...
How Hims & Hers founder Joe Spector turned 10 failures into $1B idea
Listen and subscribe to The Big Idea with Elizabeth Gore on Apple Podcasts, Spotify, or wherever you find your favorite podcast. How do you break into a tough market and win?
Customers Say Care Through Hims & Hers Matches, or Beats, the Doctor's Office
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS) today published a new white paper - Understanding Hims & Hers Approach to Clinical Excellence, Quality, and Safety - detailing how...